Clinical Trial

An Initial Evaluation of AN8025 in Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine the appropriate dose of AN8025 for use in the treatment of advanced solid tumors. This study will be conducted in in adults \>18 years of age. The main questions to answer: 1. Determine which dose level of AN8025 is safe and tolerability in participants with advanced solid tumors 2. To determine the maximum tolerated of AN8025 for future testing. Participants will visit their study site in 3 week cycles, during which they will be under go treatment with AN8025 and visit their clinical site during each cycle for check ups and testing.
Trial Details
NCT Number NCT07639047
Lead Sponsor Adlai Nortye Biopharma Co., Ltd.
Conditions Advanced Solid Tumor (Phase 1)
Enrollment 91 participants
Start Date 2025-11-01
Primary Completion 2027-07 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-10